My hope is that what I have shared here will convince others of the powerful opportunity we all have to rise up against prevailing messages intent on keeping us powerless, and to experience in the company of others our ability to effect change. May we all have strong hearts and loving companions for such a journey.
Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) Receives Average Recommendation of Moderate Buy from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.